Immunogenicity and Reactogenicity of a Meningococcal B Outer Membrane Vesicle Vaccine Given in a 0,6,12 Month Schedule to Health UK Adults
To measure the serum bactericidal antibody levels and cell mediated immune responses before and six weeks after each dose of meningococcal outer membrane vesicle vaccine given at 0,6 and 12 weeks to healthy UK adults.
Biological: Meningococcal outer membrane vesicle vaccine "MenBVac"
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Please refer to this study by its ClinicalTrials.gov identifier: NCT00197795
|Principal Investigator:||Elizabeth Miller, MBBS FRCPath||Health Protection Agency, United Kingdom|